Figure 7.
Figure 7. High-dose immunosuppressive therapy (HDIT) for multiple sclerosis (MS). / A. Survival and MS progression after HDIT. Estimated survival was 91% and MS progression was 27% at 3 years. B. Distribution of changes in Extended Disability Status Scale (EDSS) scores at 3, 12, and 24 months after HDIT as compared to baseline. / From Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. In press. Copyright American Society of Hematology, used with permission.

High-dose immunosuppressive therapy (HDIT) for multiple sclerosis (MS).

A. Survival and MS progression after HDIT. Estimated survival was 91% and MS progression was 27% at 3 years. B. Distribution of changes in Extended Disability Status Scale (EDSS) scores at 3, 12, and 24 months after HDIT as compared to baseline.

From Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. In press. Copyright American Society of Hematology, used with permission.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal